<?xml version="1.0" encoding="UTF-8"?>
<search_results count="86">
  <query>Olysio</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT01571570</nct_id>
    <title>A Study to Assess Bioavailability &amp; Food Effect of Different Liquid and Capsule Formulations of TMC435.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Volunteers</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435 150 mg capsule</intervention>
      <intervention type="Drug">TMC435 150 mg oral suspension (20 mg/mL)</intervention>
      <intervention type="Drug">TMC435 150 mg oral solution (10 mg/mL)</intervention>
      <intervention type="Drug">TMC435 150 mg capsule concept K</intervention>
      <intervention type="Drug">TMC435 150 mg capsule concept L</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100787</other_id>
      <other_id>TMC435HPC1002</other_id>
    </other_ids>
    <first_received>January 23, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>June 24, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Comparing the bioavailability of oral solution and oral suspension formulation with the capsule formulation of TMC435 (fed state)</outcome_measure>
      <outcome_measure>Comparing the bioavailability of oral solution and oral suspension formulation of TMC435 in fed and fasted state</outcome_measure>
      <outcome_measure>Comparing the bioavailability of concept K capsule and concept L capsule formulation with the capsule formulation of TMC435 (fed state)</outcome_measure>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Acceptability of taste assessed by taste questionnaires</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01571570</url>
  </study>
  <study rank="2">
    <nct_id>NCT00882908</nct_id>
    <title>A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Ribavirin (R)</intervention>
      <intervention type="Drug">PegIFNÎ±-2a (P)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>386</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015799</other_id>
      <other_id>TMC435-TiDP16-C205</other_id>
      <other_id>2008-007147-13</other_id>
    </other_ids>
    <first_received>April 16, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>May 19, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
    <acronym>PILLAR</acronym>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Detectable or Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Greater Than or Equal to 2 log10 Drop During Treatment</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving an Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normalized ALT Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Minnesota</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00882908</url>
  </study>
  <study rank="3">
    <nct_id>NCT01241773</nct_id>
    <title>TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">raltegravir</intervention>
      <intervention type="Drug">TMC435 + raltegravir</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">TMC435 + efavirenz</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">efavirenz</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017494</other_id>
    </other_ids>
    <first_received>October 21, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>November 7, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Absorption of TMC435 following co-administration with efavirenz, and vice versa.</outcome_measure>
      <outcome_measure>Absorption of TMC435 following co-administration with raltegravir, and vice versa.</outcome_measure>
      <outcome_measure>Number of participants with Adverse Events as a measure of Safety and Tolerability - TMC435 and efavirenz.</outcome_measure>
      <outcome_measure>Number of participants with Adverse Events as a measure of Safety and Tolerability - TMC435 and raltegravir.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01241773</url>
  </study>
  <study rank="4">
    <nct_id>NCT01205139</nct_id>
    <title>TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">TDF</intervention>
      <intervention type="Drug">TMC435 + TDF</intervention>
      <intervention type="Drug">TMC435 + TMC278</intervention>
      <intervention type="Drug">TMC278</intervention>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017392</other_id>
    </other_ids>
    <first_received>September 16, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>November 23, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate and extent of absorption of TMC435 following co-administration with TMC278 under fed condition, and vice versa.</outcome_measure>
      <outcome_measure>Rate and extent of absorption of TMC435 following co-administration with TDF under fed condition, and vice versa.</outcome_measure>
      <outcome_measure>Safety and tolerability following co-administration of TMC435 and TMC278 (Panel 1)</outcome_measure>
      <outcome_measure>Safety and tolerability following co-administration of TMC435 and TDF (Panel 2)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01205139</url>
  </study>
  <study rank="5">
    <nct_id>NCT02512562</nct_id>
    <title>A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AL-335</intervention>
      <intervention type="Drug">ACH-3102</intervention>
      <intervention type="Drug">Simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alios Biopharma Inc.</lead_sponsor>
      <collaborator>Achillion Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AL-335-602</other_id>
    </other_ids>
    <first_received>July 6, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>July 29, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 on AL-335 and metabolites</outcome_measure>
      <outcome_measure>Multiple dose PK Profile, Cmax and AUC: effect of Simeprevir on AL-335 and metabolites</outcome_measure>
      <outcome_measure>Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 and Simeprevir on AL-335 and metabolites</outcome_measure>
      <outcome_measure>Safety Data: Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results</outcome_measure>
      <outcome_measure>Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, Î»z: effect of AL-335 and ACH-3102 on Simeprevir</outcome_measure>
      <outcome_measure>Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, Î»z: effect of AL-335 and Simeprevir on ACH-3102</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02512562</url>
  </study>
  <study rank="6">
    <nct_id>NCT01269294</nct_id>
    <title>TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo for TMC435</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo for TMC435</intervention>
      <intervention type="Drug">Moxifloxacin</intervention>
      <intervention type="Drug">Placebo for moxifloxacin</intervention>
      <intervention type="Drug">Placebo for TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017491</other_id>
      <other_id>TMC435-TiDP16-C117</other_id>
    </other_ids>
    <first_received>December 30, 2010</first_received>
    <start_date>January 2011</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>May 3, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in QT/QTc interval for TMC435 therapeutic dose versus placebo</outcome_measure>
      <outcome_measure>Change in QT/QTc interval for TMC435 supratherapeutic dose versus placebo</outcome_measure>
      <outcome_measure>RR interval, HR, PR interval, QRS interval and ECG morphology</outcome_measure>
      <outcome_measure>Pharmacokinetics of 150 mg TMC435 once daily for 7 days</outcome_measure>
      <outcome_measure>Pharmacokinetics of 350 mg TMC435 once daily for 7 days</outcome_measure>
      <outcome_measure>Changes from baseline for electrocardiogram (ECG) and physical examination</outcome_measure>
      <outcome_measure>Number of participants with adverse events and severity of adverse events</outcome_measure>
      <outcome_measure>Changes from baseline and percentage of subjects with abnormal values for laboratory parameters</outcome_measure>
      <outcome_measure>Changes from baseline and percentage of subjects with abnormal values for pulse and blood pressure</outcome_measure>
      <outcome_measure>Difference of QTc between moxifloxacin treatment and placebo treatment as a measure for trial sensitivity</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01269294</url>
  </study>
  <study rank="7">
    <nct_id>NCT00561353</nct_id>
    <title>A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon (PegIFNÎ±-2a)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR012607</other_id>
      <other_id>TMC435350-TiDP16-C201</other_id>
    </other_ids>
    <first_received>November 19, 2007</first_received>
    <start_date>January 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>May 14, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-NaÃ¯ve HCV-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-NaÃ¯ve HCV-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-NaÃ¯ve HCV-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-NaÃ¯ve HCV-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Virologic Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Virologic Response Parameters in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)</outcome_measure>
      <outcome_measure>Virologic Response Parameters Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Viral Breakthrough in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1, Panel A and B)</outcome_measure>
      <outcome_measure>Viral Breakthrough in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Viral Relapse in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)</outcome_measure>
      <outcome_measure>Viral Relapse in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Predose Plasma Concentration (C0h) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Predose Plasma Concentration (C0h) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00561353</url>
  </study>
  <study rank="8">
    <nct_id>NCT01288742</nct_id>
    <title>TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rosuvastatin</intervention>
      <intervention type="Drug">Rosuvastatin</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Digoxin</intervention>
      <intervention type="Drug">Digoxin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017770</other_id>
      <other_id>TMC435-TiDP16-C108</other_id>
    </other_ids>
    <first_received>January 20, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>November 29, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in absorption of TMC435 following co-administration with Digoxin (Panel 1).</outcome_measure>
      <outcome_measure>Change in absorption of Digoxin following co-administration with TMC435 (Panel 1).</outcome_measure>
      <outcome_measure>Change in absorption of TMC435 following co-administration with rosuvastatin (Panel 2).</outcome_measure>
      <outcome_measure>Change in absorption of rosuvastatin following co-administration with TMC435 (Panel 2).</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability - TMC435 and Digoxin</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability - TMC435 and rosuvastatin</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01288742</url>
  </study>
  <study rank="9">
    <nct_id>NCT00980330</nct_id>
    <title>A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a (P)</intervention>
      <intervention type="Drug">Ribavirin (R)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>463</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016063</other_id>
      <other_id>TMC435-TiDP16-C206</other_id>
      <other_id>2009-010590-20</other_id>
    </other_ids>
    <first_received>September 10, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>May 30, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
    <acronym>ASPIRE</acronym>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Greater Than 2 log10 Drop in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Time Points During Treatment</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Detectable or Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving an Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants Who Achieved Normalized Alanine Aminotransferase (ALT) Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>New Zealand</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Russian Federation</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Mississippi</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00980330</url>
  </study>
  <study rank="10">
    <nct_id>NCT01479881</nct_id>
    <title>A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">tacrolimus</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">cyclosporine</intervention>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100686</other_id>
      <other_id>TMC435-TIDP16-C120</other_id>
      <other_id>2011-003021-96</other_id>
    </other_ids>
    <first_received>October 20, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>October 31, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the steady-state plasma concentration (PK) of cyclosporine and tacrolimus following co-administration with TMC435.</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability when combining TMC435 (150 mg, q.d.) with cyclosporine or tacrolimus.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01479881</url>
  </study>
  <study rank="11">
    <nct_id>NCT01323257</nct_id>
    <title>TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">erythromycin</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Darunavir</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">erythromycin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018010</other_id>
      <other_id>TMC435-TiDP16-C115</other_id>
    </other_ids>
    <first_received>March 10, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>October 10, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with erythromycin (Panel 1).</outcome_measure>
      <outcome_measure>Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with DRV/r (Panel 2).</outcome_measure>
      <outcome_measure>Change in the steady-state plasma pharmacokinetics of erythromycin following co-administration with TMC435 (Panel 1).</outcome_measure>
      <outcome_measure>Change in the steady-state plasma pharmacokinetics of DRV/r following co-administration with TMC435 (Panel 2).</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability - TMC435 and erythromycin</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability - TMC435 and DRV/r</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01323257</url>
  </study>
  <study rank="12">
    <nct_id>NCT01046058</nct_id>
    <title>TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016783</other_id>
      <other_id>TMC435-TiDP16-C113</other_id>
    </other_ids>
    <first_received>January 7, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>October 11, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetic profile of TMC435 in patients with moderate and severe hepatic impairment</outcome_measure>
      <outcome_measure>Short-term safety and tolerability of TMC435 in volunteers with moderate or severe hepatic impairment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01046058</url>
  </study>
  <study rank="13">
    <nct_id>NCT01090700</nct_id>
    <title>TMC435-TiDP16-C112 - Interaction Trial With Antidepressants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Escitalopram</intervention>
      <intervention type="Drug">TMC435 + Escitalopram</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017044</other_id>
    </other_ids>
    <first_received>March 11, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>April 8, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To investigate the effect of stable blood levels of TMC 435 given 150 mg q.d. on the stable blood levels of escitalopram given 10 mg q.d. in healthy participants and vica versa.</outcome_measure>
      <outcome_measure>The short-term safety and tolerability of coadministration of TMC435 and escitalopram in healthy participants (safety and tolerability criteria are the activity of the heart, blood pressure, pulse, physical examination, parameters in urine and blood)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01090700</url>
  </study>
  <study rank="14">
    <nct_id>NCT01707342</nct_id>
    <title>A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Male Participants</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir (TMC435)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100901</other_id>
      <other_id>TMC435-TiDP16-C118</other_id>
      <other_id>2012-002330-37</other_id>
    </other_ids>
    <first_received>October 12, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>March 27, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Absolute bioavailability of simeprevir (TMC435)</outcome_measure>
      <outcome_measure>Volume of distribution of [3H]-TMC435 and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration of simeprevir (TMC435), [3H]-TMC435, and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Time to reach the maximum observed plasma concentration of simeprevir (TMC435), [3H]-TMC435, and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Area under the concentration versus time curve from time of administration up to the last time point with a measurable concentration post dosing of simeprevir (TMC435), [3H]-TMC435, and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Area under the concentration versus time curve extrapolated to infinity of simeprevir (TMC435), [3H]-TMC435, and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Area under the first moment of the concentration versus time curve from the time of dosing up to a definite time, to infinity, or to the time of the last measureable concentration of [3H]-TMC435 and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Mean residence time of [3H]-TMC435 and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Terminal elimination rate constant of simeprevir (TMC435), [3H]-TMC435, and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Terminal elimination half-life of simeprevir (TMC435), [3H]-TMC435, and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Total systemic clearance of drug following single-dose intravenous administration of [3H]-TMC435 and [3H]-total radioactivity</outcome_measure>
      <outcome_measure>Total radioactivity excreted into the feces from time 0 to the time of discharge</outcome_measure>
      <outcome_measure>Total radioactivity excreted into the feces expressed as a percentage of the administered dose</outcome_measure>
      <outcome_measure>Total radioactivity excreted into urine from time 0 to the time of discharge</outcome_measure>
      <outcome_measure>Total radioactivity excreted into the urine expressed as a percentage of the administered dose</outcome_measure>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01707342</url>
  </study>
  <study rank="15">
    <nct_id>NCT01308606</nct_id>
    <title>TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435 HPMC capsule</intervention>
      <intervention type="Drug">TMC435 HPMC or gelatin capsule</intervention>
      <intervention type="Drug">TMC435 HPMC or gelatin capsule</intervention>
      <intervention type="Drug">TMC435 HPMC or gelatin capsule</intervention>
      <intervention type="Drug">TMC435 gelatin capsule</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015940</other_id>
      <other_id>TMC435-TiDP16-C116</other_id>
    </other_ids>
    <first_received>March 3, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>October 10, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Absorption of TMC435 following administration of the HPMC capsule and of the gelatin capsule</outcome_measure>
      <outcome_measure>Absorption of TMC435 following administration of the HPMC or gelatin capsule in the fed (following different meal types) and fasted state</outcome_measure>
      <outcome_measure>Number of participants with adverse events and the severity of adverse events</outcome_measure>
      <outcome_measure>Percentage of abnormal values for laboratory parameters</outcome_measure>
      <outcome_measure>Observed values and changes from baseline of cardiovascular variables</outcome_measure>
      <outcome_measure>Evaluation of pulse and blood pressure values, based on changes from baseline and the percentage of participants with values beyond clinically important limits</outcome_measure>
      <outcome_measure>Physical examination findings and changes from baseline.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01308606</url>
  </study>
  <study rank="16">
    <nct_id>NCT02262728</nct_id>
    <title>An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105028</other_id>
      <other_id>TMC435HPC2010</other_id>
    </other_ids>
    <first_received>October 6, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>January 2020</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After end of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants with On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR 4 Weeks After end of Study Drug Treatment (SVR4) and SVR 24 Weeks After end of Study Drug Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants with On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants with Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in HCV NS3/4A Sequence, NS5A and NS5B at Day 3, Week 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and Year 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 After end of Treatment in Participants not Achieving SVR</outcome_measure>
      <outcome_measure>Percentage of Participants with Normalized Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels</outcome_measure>
      <outcome_measure>Time to Reach Maximum Plasma Concentration (Tmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-Time Curve from Time 0 to 24 hours After Dosing (AUC[0-24]) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Pre-dose (trough) Concentration (C0h) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR12 who Maintain to have HCV RNA &lt;LLOQ Until the end of 5 years Follow up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02262728</url>
  </study>
  <study rank="17">
    <nct_id>NCT02064842</nct_id>
    <title>A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Ritonavir (RTV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR103540</other_id>
      <other_id>TMC435HPC1011</other_id>
      <other_id>2013-004236-30</other_id>
    </other_ids>
    <first_received>February 14, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>May 15, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part 1: Number of participants with adverse events following the administration of TMC647055</outcome_measure>
      <outcome_measure>Part 1: Maximum observed plasma concentration of TMC647055</outcome_measure>
      <outcome_measure>Part 1: The actual sampling time to reach the maximum observed plasma of TMC647055</outcome_measure>
      <outcome_measure>Part 1: The actual sampling time of last measurable plasma concentration of TMC647055</outcome_measure>
      <outcome_measure>Part 1: Area under curve (AUC) of TMC647055</outcome_measure>
      <outcome_measure>Part 2: Maximum observed plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Part 2: The actual sampling time to reach the maximum observed plasma of TMC435</outcome_measure>
      <outcome_measure>Part 2: Area under curve (AUC) of TMC435</outcome_measure>
      <outcome_measure>Part 2: Maximum observed plasma concentration of TMC647055</outcome_measure>
      <outcome_measure>Part 2: The actual sampling time to reach the maximum observed plasma of TMC647055</outcome_measure>
      <outcome_measure>Part 2: Area under curve (AUC) of TMC647055</outcome_measure>
      <outcome_measure>Part 2: Maximum observed plasma concentration of ritonavir (RTV)</outcome_measure>
      <outcome_measure>Part 2: The actual sampling time to reach the maximum observed plasma of ritonavir (RTV)</outcome_measure>
      <outcome_measure>Part 2: Area under curve (AUC) of ritonavir (RTV)</outcome_measure>
      <outcome_measure>Part 2: Number of participants with adverse events following the administration of TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02064842</url>
  </study>
  <study rank="18">
    <nct_id>NCT02018536</nct_id>
    <title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK2336805 30 mg</intervention>
      <intervention type="Drug">GSK2336805 60 mg</intervention>
      <intervention type="Drug">GSK2336805 120 mg</intervention>
      <intervention type="Drug">TMC435 150 mg (Treatment A)</intervention>
      <intervention type="Drug">GSK2336805 60 mg (Treatment B and part of Treatment C and D)</intervention>
      <intervention type="Drug">TMC435 100 mg (part of Treatment C)</intervention>
      <intervention type="Drug">TMC435 150 mg (part of treatment D)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR102928</other_id>
      <other_id>TMC435HPC1012</other_id>
    </other_ids>
    <first_received>December 17, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>June 16, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part 1: Maximum observed plasma concentration of GSK2336805</outcome_measure>
      <outcome_measure>Part 1: Area under the plasma concentration-time curve of GSK2336805</outcome_measure>
      <outcome_measure>Part 1: The actual sampling time to reach the maximum observed plasma concentration of GSK2336805</outcome_measure>
      <outcome_measure>Part 2: Maximum observed plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Part 2: Area under the plasma concentration-time curve of TMC435</outcome_measure>
      <outcome_measure>Part 2: The actual sampling time to reach the maximum observed plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Part 2: Maximum observed plasma concentration of GSK2336805</outcome_measure>
      <outcome_measure>Part 2: Area under the plasma concentration-time curve of GSK2336805</outcome_measure>
      <outcome_measure>Part 2: The actual sampling time to reach the maximum observed plasma concentration of GSK2336805</outcome_measure>
      <outcome_measure>Part 1 and 2: Number of participants with adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02018536</url>
  </study>
  <study rank="19">
    <nct_id>NCT02071355</nct_id>
    <title>A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435 100 mg</intervention>
      <intervention type="Drug">TMC435 150 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018526</other_id>
      <other_id>TMC435HPC1001</other_id>
    </other_ids>
    <first_received>February 24, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 28, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predose plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Minimum plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Maximum plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Time to reach the maximum plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of TMC435 from time of administration up to 24 hours after dosing</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of TMC435 from time of administration up to the last time point with a measurable concentration after dosing</outcome_measure>
      <outcome_measure>Average steady-state plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Fluctuation index of TMC435</outcome_measure>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02071355</url>
  </study>
  <study rank="20">
    <nct_id>NCT02206932</nct_id>
    <title>A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV CDC Category A1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir + Simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TMC435HPC2008</other_id>
    </other_ids>
    <first_received>July 30, 2014</first_received>
    <last_updated>November 21, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12 (HCV RNA &lt;LLOQ, or lower limit of quantification)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02206932</url>
  </study>
  <study rank="21">
    <nct_id>NCT01689623</nct_id>
    <title>A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Participants</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Atorvastatin</intervention>
      <intervention type="Drug">Simvastatin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100873</other_id>
      <other_id>TMC435HPC1006</other_id>
    </other_ids>
    <first_received>July 30, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>March 1, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effect of steady-state (constant concentration of medication in the blood) concentrations of TMC435 on the single dose pharmacokinetics (what the body does to the drug) of simvastatin and the active metabolite simvastatin acid</outcome_measure>
      <outcome_measure>Effect of steady-state concentrations of TMC435 on the single dose pharmacokinetics of atorvastatin and the active metabolites ortho- and parahydroxylated atorvastatin</outcome_measure>
      <outcome_measure>Plasma hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitory activity after a single dose of atorvastatin or simvastatin, either alone or in combination with TMC435</outcome_measure>
      <outcome_measure>To evaluate the steady-state pharmacokinetics of TMC435 in the presence of atorvastatin or simvastatin</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Nebraska</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01689623</url>
  </study>
  <study rank="22">
    <nct_id>NCT00915564</nct_id>
    <title>A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Other">Methadone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015934</other_id>
      <other_id>TMC435-TIDP16-C110</other_id>
    </other_ids>
    <first_received>June 4, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>October 11, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predose plasma concentration of S-methadone</outcome_measure>
      <outcome_measure>Maximum plasma concentration of S-methadone</outcome_measure>
      <outcome_measure>Minimum plasma concentration between 0 hour and dosing interval of S-methadone</outcome_measure>
      <outcome_measure>Average steady-state plasma concentration of S-methadone</outcome_measure>
      <outcome_measure>Time to reach the maximum plasma concentration of S-methadone</outcome_measure>
      <outcome_measure>Area under the curve from time of administration up to 24 hours post dosing of S-methadone</outcome_measure>
      <outcome_measure>Fluctuation index of S-methadone, ie, percentage fluctuation (variation between maximum and minimum concentration at steady-state)</outcome_measure>
      <outcome_measure>Predose plasma concentration of R-methadone</outcome_measure>
      <outcome_measure>Maximum plasma concentration of R-methadone</outcome_measure>
      <outcome_measure>Minimum plasma concentration between 0 hour and dosing interval of R- and S-methadone</outcome_measure>
      <outcome_measure>Average steady-state plasma concentration of R-methadone</outcome_measure>
      <outcome_measure>Time to reach the maximum plasma concentration of R-methadone</outcome_measure>
      <outcome_measure>Area under the curve from time of administration up to 24 hours post dosing of R-methadone</outcome_measure>
      <outcome_measure>Fluctuation index of R-methadone, ie, percentage fluctuation (variation between maximum and minimum concentration at steady-state)</outcome_measure>
      <outcome_measure>Predose plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Maximum plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Minimum plasma concentration between 0 hour and dosing interval of TMC435</outcome_measure>
      <outcome_measure>Average steady-state plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Time to reach the maximum plasma concentration of TMC435</outcome_measure>
      <outcome_measure>Area under the curve from time of administration up to 24 hours post dosing of TMC435</outcome_measure>
      <outcome_measure>Fluctuation index of TMC435, ie, percentage fluctuation (variation between maximum and minimum concentration at steady-state)</outcome_measure>
      <outcome_measure>Short Opiate Withdrawal Scale Scores</outcome_measure>
      <outcome_measure>Desires for Drugs Questionnaire</outcome_measure>
      <outcome_measure>Resting pupil diameter</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00915564</url>
  </study>
  <study rank="23">
    <nct_id>NCT01224197</nct_id>
    <title>TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017482</other_id>
    </other_ids>
    <first_received>October 18, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>May 7, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>plasma concentration of TMC435 after a single oral dose of 100 and 200 mg TMC435 in healthy Chinese volunteers in fed conditions</outcome_measure>
      <outcome_measure>plasma concentration of TMC435 after a multiple oral dose of 100 and 200 mg TMC435 in healthy Chinese volunteers in fed conditions</outcome_measure>
      <outcome_measure>Safety and tolerability of TMC435 after single oral dose of 100 and 200 mg in healthy Chinese volunteers</outcome_measure>
      <outcome_measure>Safety and tolerability of TMC435 after multiple oral dose of 100 and 200 mg q.d. for 5 days in healthy Chinese volunteers</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Hong Kong</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01224197</url>
  </study>
  <study rank="24">
    <nct_id>NCT02165189</nct_id>
    <title>An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitits C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Scientific Affairs, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR104281</other_id>
      <other_id>TMC435HPC2009</other_id>
    </other_ids>
    <first_received>June 10, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>October 21, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GALAXY</acronym>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 12 Weeks of end of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 4 Weeks of end of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in Hepatitis C Symptom and Impact Questionnaire Version 4 (HCV-SIQv4) Score at Week 24 (for Arms 1 and 2) and Week 36 (for Arm 3)</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Questionnaire Score at Weeks 4, 8, 12, 16, 20, 24 (for all treatment arms) and Week 36 (for Arm 3)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02165189</url>
  </study>
  <study rank="25">
    <nct_id>NCT02250807</nct_id>
    <title>Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 4 Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105429</other_id>
      <other_id>TMC435HPC3021</other_id>
      <other_id>2014-003446-27</other_id>
    </other_ids>
    <first_received>September 24, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>September 25, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Sustained Virologic Response (SVR 12) at Week 12 After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Virologic Response at Week 4 (SVR 4) and 24 (SVR 24) After EOT</outcome_measure>
      <outcome_measure>Percentage of Subjects With On-treatment Virologic Response of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Subjects With on-treatment failure along with Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Subjects With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02250807</url>
  </study>
  <study rank="26">
    <nct_id>NCT01124799</nct_id>
    <title>TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Ciprofloxacin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017158</other_id>
    </other_ids>
    <first_received>May 13, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>May 3, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The effect of TMC435 versus placebo on the sensitivity of the skin towards sun light</outcome_measure>
      <outcome_measure>Rate and extent of absorption of TMC435 and ciprofloxacin in the blood circulation</outcome_measure>
      <outcome_measure>Number of participants with Adverse Events as measures for Safety and Tolerability..</outcome_measure>
      <outcome_measure>Number of Adverse Events (per type) as measures for Safety and Tolerability.</outcome_measure>
      <outcome_measure>Results of clinical laboratory evaluations as measures for Safety and Tolerability.</outcome_measure>
      <outcome_measure>Vital signs including ECG monitoring as measures for Safety and Tolerability.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01124799</url>
  </study>
  <study rank="27">
    <nct_id>NCT01366638</nct_id>
    <title>A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (pegIFN alfa-2b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>79</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017935</other_id>
      <other_id>TMC435HPC3010</other_id>
    </other_ids>
    <first_received>June 2, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>April 10, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNÎ±-2b) and Ribavirin (RBV) at Week 24</outcome_measure>
      <outcome_measure>The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01366638</url>
  </study>
  <study rank="28">
    <nct_id>NCT01134718</nct_id>
    <title>TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435 (G006)</intervention>
      <intervention type="Drug">TMC435 (F021)</intervention>
      <intervention type="Drug">TMC435 (G007)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017155</other_id>
    </other_ids>
    <first_received>May 28, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>April 8, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate and extent of absorption of TMC435 following administration of 3 different capsule formulations under fed condition</outcome_measure>
      <outcome_measure>All reported Adverse Events + percentage of subjects who experienced at least 1 occurrence of a given event as a measure of Safety and Tolerability following administration of single doses of 150 mg TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01134718</url>
  </study>
  <study rank="29">
    <nct_id>NCT01486004</nct_id>
    <title>A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Ovysmen</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100683</other_id>
      <other_id>TMC435-TiDP16-C124</other_id>
      <other_id>2011-003022-26</other_id>
    </other_ids>
    <first_received>October 21, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>January 30, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the steady-state plasma PK of ethinylestradiol following co-administration with TMC435</outcome_measure>
      <outcome_measure>Change in the steady-state plasma PK of norethindrone following co-administration with TMC435</outcome_measure>
      <outcome_measure>Change in the plasma levels of progesterone following co-administration of Ovysmen and TMC435.</outcome_measure>
      <outcome_measure>Number of participants (%) with adverse events as a measure of safety and tolerability when combining TMC435 (150 mg, q.d.) with Ovysmen (35 Âµg ethinylestradiol + 1 mg norethindrone, q.d.)</outcome_measure>
      <outcome_measure>Change in the plasma levels of luteinizing hormone following co-administration of Ovysmen and TMC435.</outcome_measure>
      <outcome_measure>Change in the plasma levels of follicle-stimulating hormone following co-administration of Ovysmen and TMC435.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01486004</url>
  </study>
  <study rank="30">
    <nct_id>NCT02404805</nct_id>
    <title>Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">dolutegravir</intervention>
      <intervention type="Drug">simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>15-0106</other_id>
      <other_id>152252</other_id>
    </other_ids>
    <first_received>March 18, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Simeprevir AUC Pharmacokinetics</outcome_measure>
      <outcome_measure>Dolutegravir AUC Pharmacokinetics</outcome_measure>
      <outcome_measure>Simeprevir AUC Pharmacokinetics Coadministered With Dolutegravir</outcome_measure>
      <outcome_measure>Dolutegravir AUC Pharmacokinetics Coadministered With Simeprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02404805</url>
  </study>
  <study rank="31">
    <nct_id>NCT01289782</nct_id>
    <title>An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alpha-2a (PegIFN alpha-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>395</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017386</other_id>
      <other_id>TMC435-TiDP16-C208</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>May 20, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>January 27, 2014</firstreceived_results_date>
    <acronym>QUEST-1</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) in Work Productivity and Activity (WPAI) Absenteeism Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Germany</country>
      <country>Mexico</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01289782</url>
  </study>
  <study rank="32">
    <nct_id>NCT01281839</nct_id>
    <title>An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alpha-2a (PegIFN alpha-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>394</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017371</other_id>
      <other_id>TMC435HPC3007</other_id>
      <other_id>2010-021113-23</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>March 26, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <acronym>PROMISE</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>The Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>The Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>The Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>The Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01281839</url>
  </study>
  <study rank="33">
    <nct_id>NCT01725529</nct_id>
    <title>An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon-alpha (PegIFNÎ±-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>457</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017962</other_id>
      <other_id>TMC435HPC3005</other_id>
    </other_ids>
    <first_received>November 9, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>July 15, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 15, 2015</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After End of Study Drug Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Normalization of Alanine Aminotransferase Level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01725529</url>
  </study>
  <study rank="34">
    <nct_id>NCT01813513</nct_id>
    <title>Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IDX719</intervention>
      <intervention type="Drug">Simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1894-004</other_id>
      <other_id>IDX-06A-004</other_id>
    </other_ids>
    <first_received>March 13, 2013</first_received>
    <start_date>January 2013</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>February 5, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area under the plasma concentration-time curve (AUC) at steady-state over dosing interval (AUCss)</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>AUC from time zero to infinity</outcome_measure>
      <outcome_measure>Trough plasma concentration (Ctrough)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing adverse events (AEs)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing Grade 1-4 laboratory abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01813513</url>
  </study>
  <study rank="35">
    <nct_id>NCT01290679</nct_id>
    <title>An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNÎ±-2a/b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>393</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017380</other_id>
      <other_id>TMC435-TiDP16-C216</other_id>
      <other_id>2010-021174-11</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>June 10, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <acronym>QUEST-2</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activities Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Time Missed From Work Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Minnesota</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01290679</url>
  </study>
  <study rank="36">
    <nct_id>NCT01891851</nct_id>
    <title>A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435350 200 mg</intervention>
      <intervention type="Drug">Ritonavir 100 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR014773</other_id>
      <other_id>TMC435350-TiDP16-C104</other_id>
    </other_ids>
    <first_received>June 28, 2013</first_received>
    <start_date>October 2007</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>October 11, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Plasma concentration of TMC435350</outcome_measure>
      <outcome_measure>Number of patients reporting adverse events (AEs) as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01891851</url>
  </study>
  <study rank="37">
    <nct_id>NCT01938625</nct_id>
    <title>A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR102639</other_id>
      <other_id>TMC435HPC3016</other_id>
      <other_id>2013-002726-23</other_id>
    </other_ids>
    <first_received>September 5, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with a sustained virologic response (SVR)12 Weeks after the end of treatment</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of cyclosporine and tacrolimus</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[last]) of cyclosporine and tacrolimus</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of simprevir and daclatasvir</outcome_measure>
      <outcome_measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of simprevir and daclatasvir</outcome_measure>
      <outcome_measure>Predose (trough) concentration (C0h) of simprenavir and daclatasvir</outcome_measure>
      <outcome_measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of simprevir and daclatasvir</outcome_measure>
      <outcome_measure>Number of participants with dose adjustment of cyclosporine and tacrolimus during treatment with regimen simeprevir, daclatasvir and RBV</outcome_measure>
      <outcome_measure>Number of patients with a sustained virological response SVR4 after the end of treatment</outcome_measure>
      <outcome_measure>Number of participants with a sustained virologic response SVR24 after the end of treatment</outcome_measure>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Number of participants with Undetectable HCV RNA (less than 25 IU/mL undetectable) and HCV RNA less than 25 IU/mL detectable</outcome_measure>
      <outcome_measure>Number of participants with HCV RNA level less than 100 IU/mL</outcome_measure>
      <outcome_measure>Number of participants with on-treatment failure after treatment with regimen simeprevir, daclatasvir and RBV</outcome_measure>
      <outcome_measure>Number of participants with viral relapse after treatment with regimen simeprevir, daclatasvir and RBV</outcome_measure>
      <outcome_measure>Number of participants with HCV NS3/4A and NS5A sequences</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
      <country>Poland</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01938625</url>
  </study>
  <study rank="38">
    <nct_id>NCT01907724</nct_id>
    <title>Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IDX719</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">RTV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Janssen Research &amp; Development, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1894-007</other_id>
      <other_id>IDX-06A-007</other_id>
    </other_ids>
    <first_received>June 4, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>February 5, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Observed maximum plasma drug concentration (Cmax)</outcome_measure>
      <outcome_measure>Time to maximum concentration (Tmax)</outcome_measure>
      <outcome_measure>Area under the drug concentration-plasma time curve from time zero to last measurable concentration (AUC0-t)</outcome_measure>
      <outcome_measure>Predose trough concentration (Ctrough)</outcome_measure>
      <outcome_measure>Apparent terminal elimination rate constant</outcome_measure>
      <outcome_measure>Observed terminal half-life (T1/2)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing adverse events (AEs)</outcome_measure>
      <outcome_measure>Percentage of participants with Grade 1-4 laboratory abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01907724</url>
  </study>
  <study rank="39">
    <nct_id>NCT01799603</nct_id>
    <title>A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100854</other_id>
      <other_id>TMC435HPC1007</other_id>
    </other_ids>
    <first_received>February 25, 2013</first_received>
    <start_date>May 2012</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>April 25, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Plasma Concentration (C[max])</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[infinity])</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01799603</url>
  </study>
  <study rank="40">
    <nct_id>NCT02253550</nct_id>
    <title>Simeprevir in Combination With Sofosbuvir in Treatment-NaÃ¯ve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Peter J. Ruane, M.D.</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
      <collaborator>Peter J. Ruane, M.D., Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TMC435HPC2012</other_id>
    </other_ids>
    <first_received>September 17, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>June 20, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response 12 Weeks after Treatment Completion (SVR12)</outcome_measure>
      <outcome_measure>Sustained Virologic Response 4 and 24 Weeks after Treatment Completion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02253550</url>
  </study>
  <study rank="41">
    <nct_id>NCT00741169</nct_id>
    <title>TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HCV</condition>
      <condition>Tuberculosis</condition>
      <condition>Rifampin</condition>
      <condition>Pharmacokinetics</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435350</intervention>
      <intervention type="Drug">Rifampin</intervention>
      <intervention type="Drug">TMC435350+rifampin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015412</other_id>
    </other_ids>
    <first_received>August 22, 2008</first_received>
    <start_date>June 2008</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>April 17, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetic (PK) profile of TMC435350</outcome_measure>
      <outcome_measure>Pharmacokinetic (PK) profile of rifampin and 25-deacetylrifampin</outcome_measure>
      <outcome_measure>The number of participants reporting adverse events as a measure of safety and tolerability.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00741169</url>
  </study>
  <study rank="42">
    <nct_id>NCT01567735</nct_id>
    <title>A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-NaÃ¯ve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100695</other_id>
      <other_id>TMC435HPC3011</other_id>
      <other_id>2011-004097-29</other_id>
    </other_ids>
    <first_received>January 24, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>April 13, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RESTORE</acronym>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>Efficacy of TMC435 with respect to proportion of participants achieving sustained virologic response 24 weeks after planned end of treatment (SVR24)</outcome_measure>
      <outcome_measure>On-treatment virologic response</outcome_measure>
      <outcome_measure>On-treatment virologic failure</outcome_measure>
      <outcome_measure>Evaluation of the viral breakthrough rate</outcome_measure>
      <outcome_measure>Evaluation of viral relapse rate</outcome_measure>
      <outcome_measure>Evaluation the safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01567735</url>
  </study>
  <study rank="43">
    <nct_id>NCT01381835</nct_id>
    <title>TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017953</other_id>
      <other_id>TMC435-TiDP16-C126</other_id>
    </other_ids>
    <first_received>June 23, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>October 11, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change in the steady-state plasma pharmacokinetics of TMC435 following administration in participants with severe renal impairement, as compared to the matching healthy participants.</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01381835</url>
  </study>
  <study rank="44">
    <nct_id>NCT01292239</nct_id>
    <title>A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alfa-2a (pegIFN alfa-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>183</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017686</other_id>
      <other_id>TMC435HPC3003</other_id>
    </other_ids>
    <first_received>February 1, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>December 16, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>October 15, 2013</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Levels of Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants in the TMC435 Treatment Group Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFN Alpha-2a) and Ribavirin (RBV) at Week 24</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01292239</url>
  </study>
  <study rank="45">
    <nct_id>NCT02624063</nct_id>
    <title>Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir + Sofosbuvir</intervention>
      <intervention type="Drug">Simeprevir + Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federal University of SÃ£o Paulo</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>394</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TNT</other_id>
    </other_ids>
    <first_received>December 2, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>December 3, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Sustained Virologic Response at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Rapid Virologic Response at Week 4 (RVR)</outcome_measure>
      <outcome_measure>Percentage of Subjects With End of Treatment Response (EOTR)</outcome_measure>
      <outcome_measure>Treatment safety measured by the number of incidence of serious adverse event (SAEs), discontinuations due to adverse event (AEs), Grade 3/4 AEs and Grade 3/4 clinical laboratory abnormalities through the end of treatment.</outcome_measure>
      <outcome_measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Relapse at Follow-up Week 12 (SVR12)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02624063</url>
  </study>
  <study rank="46">
    <nct_id>NCT02385071</nct_id>
    <title>A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Treatment A</intervention>
      <intervention type="Drug">Treatment B</intervention>
      <intervention type="Drug">Treatment C</intervention>
      <intervention type="Drug">Treatment D</intervention>
      <intervention type="Drug">Treatment E</intervention>
      <intervention type="Drug">Treatment F</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Sciences Ireland UC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR106516</other_id>
      <other_id>TMC435HPC1010</other_id>
    </other_ids>
    <first_received>March 5, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>September 21, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Simeprevir (SMV)</outcome_measure>
      <outcome_measure>Time to Reach the Maximum Plasma Concentration (Tmax) of SMV</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-Time Curve From 0 to last (AUC[0-last]) Post Dose of SMV</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time (AUC[0-infinity]) Post Dose of SMV</outcome_measure>
      <outcome_measure>Elimination Rate Constant (Lambda [z]) of SMV</outcome_measure>
      <outcome_measure>Terminal Half-life (t[1/2]) of SMV</outcome_measure>
      <outcome_measure>Number of Participants within Each Category of Taste Questionnaire</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events (AEs) and Serious AEs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02385071</url>
  </study>
  <study rank="47">
    <nct_id>NCT01288209</nct_id>
    <title>A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alfa-2a (PegIFNÎ±-2a )</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017689</other_id>
      <other_id>TMC435HPC3004</other_id>
    </other_ids>
    <first_received>February 1, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>December 18, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>October 15, 2013</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During Treatment for Participants Who Did Not Achieve Undetectable Plasma HCV RNA Levels at Week 12</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough During the Study</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse During the Study</outcome_measure>
      <outcome_measure>The Number Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFNÎ±-2a) and Ribavirin (RBV) at Week 24</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01288209</url>
  </study>
  <study rank="48">
    <nct_id>NCT01479868</nct_id>
    <title>A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus Genotype-1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>109</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018334</other_id>
      <other_id>TMC435-TiDP16-C212</other_id>
    </other_ids>
    <first_received>October 18, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 28, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>August 26, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 24 (SVR 24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Less Than (&lt;) 25 International Units (IU/mL) Undetectable or Detectable/Undetectable</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With Normalized Alanine Aminotransferase Levels</outcome_measure>
      <outcome_measure>Percentage of Human Immunodeficiency Virus (HIV) Participants With Virologic Failure</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Log10 Plasma Human Immunodeficiency Virus (HIV) Viral Load</outcome_measure>
      <outcome_measure>Mean Change From Baseline in CD4+ Cell Count</outcome_measure>
      <outcome_measure>Change From Baseline in CD4+ Cell Count in Percentage</outcome_measure>
      <outcome_measure>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01479868</url>
  </study>
  <study rank="49">
    <nct_id>NCT01323244</nct_id>
    <title>A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>142</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017983</other_id>
      <other_id>TMC435-TiDP16-C213</other_id>
    </other_ids>
    <first_received>March 24, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of participants with sustained viral response</outcome_measure>
      <outcome_measure>Number of participants with HCV RNA level &gt;1000 IU/mL</outcome_measure>
      <outcome_measure>Number of participants with viral breakthrough</outcome_measure>
      <outcome_measure>Number of participants with viral relapse</outcome_measure>
      <outcome_measure>Number of participants with normalized alanine aminotransferase levels</outcome_measure>
      <outcome_measure>Number of participants with on-treatment failure</outcome_measure>
      <outcome_measure>Number of participants affected by an adverse event</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Mexico</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Louisiana</state>
      <state>Mississippi</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01323244</url>
  </study>
  <study rank="50">
    <nct_id>NCT00866853</nct_id>
    <title>TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Viruses</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015949</other_id>
    </other_ids>
    <first_received>March 19, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>April 26, 2010</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Plasma levels of TMC435, midazolam and the compounds of the cocktail (+ metabolites) will be assessed.</outcome_measure>
      <outcome_measure>To determine the short-term safety and tolerability of the concomitant use of TMC435 and oral midazolam or a cocktail of representative probes of drug-degrading enzymes of the CYP family</outcome_measure>
      <outcome_measure>To determine the steady-state pharmacokinetics of TMC435 given 150 mg once daily</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00866853</url>
  </study>
  <study rank="51">
    <nct_id>NCT01846832</nct_id>
    <title>A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a (PegIFNÎ±-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>232</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100981</other_id>
      <other_id>TMC435HPC3014</other_id>
      <other_id>2012-004905-29</other_id>
    </other_ids>
    <first_received>May 1, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion (percentage) of participants infected wtih genotype 1 HCV with a sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants infected wtih genotype 4 HCV with a sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants who achieve rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants who achieve virologic response at Week 2 (W2VR)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with sustained virologic response 24 weeks after planned end of treatment (SVR24)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with &gt; or = 2 log decrease in hepatitis C virus (HCV) RNA at each time point</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with hepatitis C virus (HCV) RNA &lt; 25 IU/mL undetectable at each time point</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with viral breakthrough</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with viral relapse</outcome_measure>
      <outcome_measure>Change from Baseline in the Hepatitis C Treatment Symptom &amp; Impact Questionnaire (HCV SIQ) symptom and impact scores</outcome_measure>
      <outcome_measure>Change from Baseline in The Fatigue Severity Scale (FSS) total score</outcome_measure>
      <outcome_measure>Change from Baseline in The Center for Epidemiologic Studies Depression Scale (CES-D) score</outcome_measure>
      <outcome_measure>Change from Baseline in The Work Productivity and Activity Index (WPAI) for Hepatitis C missed work time, daily activity impairment, and productivity scores</outcome_measure>
      <outcome_measure>Change from Baseline in The EuroQol 5 Dimension (EQ5D) Visual Analog Scale (VAS) valuation index, and Descriptive System scores</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with normalized alanine aminotransferase (ALT) levels</outcome_measure>
      <outcome_measure>Change from Screening in liver disease stage assessment</outcome_measure>
      <outcome_measure>The number of participants reporting adverse events as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Saudi Arabia</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01846832</url>
  </study>
  <study rank="52">
    <nct_id>NCT02421211</nct_id>
    <title>A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir (SMV)</intervention>
      <intervention type="Drug">Ledipasvir (LDV)</intervention>
      <intervention type="Drug">Sofosbuvir (SOF)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Sciences Ireland UC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR106992</other_id>
      <other_id>TMC435HPC2017</other_id>
      <other_id>2015-000459-25</other_id>
    </other_ids>
    <first_received>April 15, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of Simeprevir and Ledipasvir</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Simeprevir and Ledipasvir</outcome_measure>
      <outcome_measure>Area Under the Curve Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Simeprevir and Ledipasvir</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-emergent Grade 1-4 Laboratory Abnormalities</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants with Sustained Viral Response 4 Weeks After the Actual EOT (SVR4) and 12 Weeks After Actual EOT (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in HCV Nonstructural Protein (NS3/4A), Nonstructural Protein 5A (NS5A) and Nonstructural Protein 5B (NS5B) Sequence in Participants not Achieving SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02421211</url>
  </study>
  <study rank="53">
    <nct_id>NCT02114177</nct_id>
    <title>Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>310</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR103430</other_id>
      <other_id>TMC435HPC3017</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned end of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 4 Weeks After the Planned end of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 24 Weeks After the Planned end of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants with Viral Breakthrough</outcome_measure>
      <outcome_measure>Number of Participants with Viral Relapse</outcome_measure>
      <outcome_measure>Change from Baseline in Hepatitis C Symptom and Impact Questionnaire (HCV-SIQ) scores</outcome_measure>
      <outcome_measure>Change From Baseline in Fatigue Severity Scale (FSS) Scores</outcome_measure>
      <outcome_measure>Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Scores</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5 Dimension (EQ-5D) Questionnaire Scores</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02114177</url>
  </study>
  <study rank="54">
    <nct_id>NCT01022125</nct_id>
    <title>TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016744</other_id>
    </other_ids>
    <first_received>November 25, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>May 13, 2010</last_updated>
    <last_verified>May 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate and extent of absorption of TMC435 following administration of the tablet vs the capsule formulations and rate and extent of absorption of TMC435 following administration of the capsule formulation fasted or with food</outcome_measure>
      <outcome_measure>Safety and tolerability following administration of single doses of 150 mg TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01022125</url>
  </study>
  <study rank="55">
    <nct_id>NCT00996476</nct_id>
    <title>A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">PegIFNÎ±-2a</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>92</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016402</other_id>
      <other_id>TMC435-TiDP16-C215</other_id>
    </other_ids>
    <first_received>October 15, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>March 21, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
    <acronym>DRAGON</acronym>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels From Baseline to Week 4</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During the Study</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Decrease of Greater Than or Equal to 2 log10 IU/mL From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Through the Post-treatment Follow-up Period</outcome_measure>
      <outcome_measure>The Percentage of Participants With Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Undetectable or Below the Limit of Quantification (&lt;1.2 log10 IU/mL Detectable) During Treatment and During Post Treatment Follow-up</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Actual Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values up to Week 24 in the Post-treatment Follow-up Period</outcome_measure>
      <outcome_measure>The Number of Participants With Alanine Aminotransaminase (ALT) Values Within the Normal Range at the End-of-treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Predose Plasma Concentrations (C0h) of TMC435 (Sparse Blood Sampling)</outcome_measure>
      <outcome_measure>Predose Plasma Concentrations (C0h) of TMC435 (Intensive Blood Sampling)</outcome_measure>
      <outcome_measure>The Area Under the Plasma Concentration-time Curve From the Time of Administration up to 24 Hours After Dosing (AUC24) for TMC435</outcome_measure>
      <outcome_measure>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC435</outcome_measure>
      <outcome_measure>The Number of Participants Who Met Virologic Stopping/Continuation Rules and Completed All Study Medications</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00996476</url>
  </study>
  <study rank="56">
    <nct_id>NCT01628692</nct_id>
    <title>Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Janssen Research &amp; Development, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-062</other_id>
      <other_id>2012-000070-28</other_id>
    </other_ids>
    <first_received>June 25, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With End of Treatment Response (EOTR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) by rs12979860 Single Nucleotide Polymorphisms in the IL-28B Gene Categories</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01628692</url>
  </study>
  <study rank="57">
    <nct_id>NCT01466790</nct_id>
    <title>A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">PSI-7977 (GS7977)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
      <collaborator>Gilead Sciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018724</other_id>
      <other_id>TMC435HPC2002</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>January 26, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>October 17, 2014</firstreceived_results_date>
    <acronym>COSMOS</acronym>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Planned End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) 4 Weeks After the Planned End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) 24 Weeks After the Planned End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) at Week 48</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Number of Participants With Inadequate Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>New Hampshire</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01466790</url>
  </study>
  <study rank="58">
    <nct_id>NCT00812331</nct_id>
    <title>A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR012604</other_id>
      <other_id>TMC435350-TiDP16-C202</other_id>
    </other_ids>
    <first_received>December 18, 2008</first_received>
    <start_date>March 2009</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>July 1, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>December 24, 2013</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels</outcome_measure>
      <outcome_measure>Number of Participants With a Decrease From Baseline of Greater Than or Equal to 2 log10 IU/mL in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During the TMC435 Treatment Period</outcome_measure>
      <outcome_measure>Number of Participants With Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Below the Limit of Quantification (Less Than 25 IU/mL) and Limit of Detection (Less Than 25 IU/mL Undetectable) During the TMC435 Treatment Period</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced Viral Breakthrough During TMC435 Treatment Period</outcome_measure>
      <outcome_measure>Predose Plasma Concentration (C0h) of TMC435</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of TMC435</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of TMC435</outcome_measure>
      <outcome_measure>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC435</outcome_measure>
      <outcome_measure>Average Steady-State Plasma Concentration (Css,av) of TMC435</outcome_measure>
      <outcome_measure>Fluctuation Index (FI) of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From the Time of Administration up to 24 Hours After Dosing (AUC24h) of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From Time of Administration up to the Last Time Point With a Measurable Concentration After Dosing (AUClast) of TMC435</outcome_measure>
      <outcome_measure>Elimination Rate Constant of TMC435</outcome_measure>
      <outcome_measure>Terminal Elimination Half-life (t1/2,Term) of TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00812331</url>
  </study>
  <study rank="59">
    <nct_id>NCT01290731</nct_id>
    <title>A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Pegylated interferon (pegIFN alpha-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017698</other_id>
      <other_id>TMC435HPC3008</other_id>
    </other_ids>
    <first_received>February 3, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>December 16, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hrs (AUC24h) for TMC435</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01290731</url>
  </study>
  <study rank="60">
    <nct_id>NCT02278419</nct_id>
    <title>An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>63</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR104970</other_id>
      <other_id>TMC435HPC2014</other_id>
    </other_ids>
    <first_received>October 28, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>September 25, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 After End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 4 After End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 24 After End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With on-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02278419</url>
  </study>
  <study rank="61">
    <nct_id>NCT02569710</nct_id>
    <title>A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, ACH-3102, and Simeprevir</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AL-335</intervention>
      <intervention type="Drug">ACH-3102</intervention>
      <intervention type="Drug">Simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alios Biopharma Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AL-335-604</other_id>
    </other_ids>
    <first_received>October 1, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 5, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety Data: Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG, echo and abnormal clinical laboratory results</outcome_measure>
      <outcome_measure>Cmax: AL-335, ACH-3102, and Simeprevir</outcome_measure>
      <outcome_measure>AUC: AL-335, ACH-3102, and Simeprevir</outcome_measure>
      <outcome_measure>Proportion of Subjects with SVR 4 Weeks, SVR 6 Weeks, and SVR 8 Weeks After end of Study Drug Treatment</outcome_measure>
      <outcome_measure>Combination of AL-335, ACH-3102, and Simeprevir: effect on viral resistance profile after 4, 6, and 8 weeks administration</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02569710</url>
  </study>
  <study rank="62">
    <nct_id>NCT01724086</nct_id>
    <title>A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alpha-2a (PegIFN)</intervention>
      <intervention type="Drug">GSK2336805</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100882</other_id>
      <other_id>TMC647055HPC2001</other_id>
      <other_id>2012-002555-42</other_id>
    </other_ids>
    <first_received>September 26, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>January 23, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with a sustained virologic response (SVR) 12 Weeks after the actual end of treatment</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Number of patients with a sustained virological response (SVR at 4 and/or 24 Weeks after the actual end of treatment)</outcome_measure>
      <outcome_measure>HCV RNA levels over time</outcome_measure>
      <outcome_measure>Number of patients with undetectable hepatitis C virus (HCV) RNA (less than 25 IU/mL undetectable) and/or HCV RNA levels less than 25 IU/mL at all time points</outcome_measure>
      <outcome_measure>Number of patients with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Number of patients with viral relapse</outcome_measure>
      <outcome_measure>Number of patients with presence of HCV variants associated with reduced susceptibility to investigational treatment</outcome_measure>
      <outcome_measure>Maximum plasma analyte concentration of TMC435</outcome_measure>
      <outcome_measure>Minimum plasma analyte concentration of TMC435</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of TMC435</outcome_measure>
      <outcome_measure>Maximum plasma analyte concentration of TMC647055</outcome_measure>
      <outcome_measure>Minimum plasma analyte concentration of TMC647055</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of TMC647055</outcome_measure>
      <outcome_measure>Maximum plasma analyte concentration of ritonavir (RTV)</outcome_measure>
      <outcome_measure>Minimum plasma analyte concentration of RTV</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of RTV</outcome_measure>
      <outcome_measure>Minimum and maximum plasma concentrations of GSK233680k</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of GSK233680k</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01724086</url>
  </study>
  <study rank="63">
    <nct_id>NCT01852604</nct_id>
    <title>Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Samatasvir</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">Ritonavir (RTV)</intervention>
      <intervention type="Biological">Pegylated interferon (Peg-IFN)</intervention>
      <intervention type="Other">Samatasvir matching placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Janssen Research &amp; Development, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>143</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>1894-005</other_id>
      <other_id>IDX-06A-005</other_id>
    </other_ids>
    <first_received>May 6, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>April 22, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants who experienced an adverse event (AE)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced a serious adverse event (SAE)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced a Grade 1-4 laboratory abnormality</outcome_measure>
      <outcome_measure>Percentage of participants who experienced sustained virologic response 4 weeks after the end of treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced early virologic response (EVR)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced sustained virologic response 8 weeks after the end of treatment (SVR8)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced sustained virologic response 12 weeks after the end of treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced sustained virologic response 24 weeks after the end of treatment (SVR24)</outcome_measure>
      <outcome_measure>Pharmacokinetic Parameter:Area under the concentration-time curve from time zero to t</outcome_measure>
      <outcome_measure>Pharmacokinetic Parameter: Maximum observed drug concentration (Cmax)</outcome_measure>
      <outcome_measure>Pharmacokinetic Parameter: Trough drug concentration (Ctrough)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01852604</url>
  </study>
  <study rank="64">
    <nct_id>NCT02114151</nct_id>
    <title>Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR103431</other_id>
      <other_id>TMC435HPC3018</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned end of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 4 Weeks After the Planned end of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 24 Weeks After the Planned end of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants with Viral Breakthrough</outcome_measure>
      <outcome_measure>Number of Participants with Viral Relapse</outcome_measure>
      <outcome_measure>Change from baseline in Hepatitis C Symptom and Impact Questionnaire (HCV-SIQ) scores</outcome_measure>
      <outcome_measure>Change From Baseline in Fatigue Severity Scale (FSS) Scores</outcome_measure>
      <outcome_measure>Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Scores</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5 Dimension (EQ-5D) Questionnaire Scores</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02114151</url>
  </study>
  <study rank="65">
    <nct_id>NCT02268864</nct_id>
    <title>A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105490</other_id>
      <other_id>2014-003413-28</other_id>
      <other_id>TMC435HPC2019</other_id>
    </other_ids>
    <first_received>October 15, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COMMIT</acronym>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After end of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR 4 Weeks After end of Study Drug Treatment (SVR4) and SVR 24 Weeks After end of Study Drug Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants with On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants with viral breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02268864</url>
  </study>
  <study rank="66">
    <nct_id>NCT00752648</nct_id>
    <title>TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435350</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015415</other_id>
    </other_ids>
    <first_received>September 11, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>April 26, 2010</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To compare the oral bioavailability and plasma pharmacokinetics of TMC435350 for 2 different solid formulations to those of TMC435350 formulated as a powder blend in a capsule, after a single oral dose of 200 mg in healthy volunteers;</outcome_measure>
      <outcome_measure>To determine the short term safety and tolerability of TMC435350 after a single oral dose of 200 mg formulated as capsules of 2 different formulations and as a tablet in healthy volunteers.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00752648</url>
  </study>
  <study rank="67">
    <nct_id>NCT02349048</nct_id>
    <title>Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir 150 mg</intervention>
      <intervention type="Drug">Daclatasvir 60 mg</intervention>
      <intervention type="Drug">Sofosbuvir 400 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105963</other_id>
      <other_id>TMC435HPC2013</other_id>
    </other_ids>
    <first_received>January 22, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>November 19, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ACCORDION-1</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 12 Weeks After end of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 Weeks (SVR4) and 24 Weeks (SVR24) After end of Study Drug Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change from Baseline in HCV Nonstructural Protein 3/4A (NS3/4A), NS5A and NS5B Sequence in Participants not Achieving SVR</outcome_measure>
      <outcome_measure>Percentage of Participants With or Without an NS3 Q80K Polymorphism at Baseline Achieving SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>North Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02349048</url>
  </study>
  <study rank="68">
    <nct_id>NCT02397395</nct_id>
    <title>An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Renal Impairment</condition>
      <condition>End-stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir (SMV) 150 mg</intervention>
      <intervention type="Drug">Daclatasvir (DCV) 60 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR106396</other_id>
      <other_id>TMC435HPC2018</other_id>
      <other_id>2014-004250-34</other_id>
    </other_ids>
    <first_received>March 19, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>July 15, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 After End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 4 After End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 24 After End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With on-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in Hepatitis C Virus (HCV) Nonstructural Protein 3/4A (NS3/4A) and Nonstructural Protein 5A (NS5A) Sequence in Participants not Achieving SVR</outcome_measure>
      <outcome_measure>Change From Baseline in HCV Symptom and Impact Questionnaire version 4 (HCV-SIQv4) Overall Body Symptom score</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02397395</url>
  </study>
  <study rank="69">
    <nct_id>NCT02168361</nct_id>
    <title>The SIM-SOF Trial for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alfa-2b</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Center For Hepatitis C, Atlanta, GA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHC-21</other_id>
    </other_ids>
    <first_received>June 17, 2014</first_received>
    <start_date>December 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>June 19, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response 12 (SVR-12)</outcome_measure>
      <outcome_measure>Virologic Relapse</outcome_measure>
      <outcome_measure>Virologic Breakthrough</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02168361</url>
  </study>
  <study rank="70">
    <nct_id>NCT01485991</nct_id>
    <title>TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFÎ±-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFÎ±-2a and Ribavirin Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">TVR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>771</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100677</other_id>
      <other_id>TMC435HPC3001</other_id>
    </other_ids>
    <first_received>November 25, 2011</first_received>
    <start_date>February 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>March 27, 2015</firstreceived_results_date>
    <acronym>ATTAIN</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>Czech Republic</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>Israel</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>Montana</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01485991</url>
  </study>
  <study rank="71">
    <nct_id>NCT02485080</nct_id>
    <title>Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>PT-NANBH</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>33431</other_id>
    </other_ids>
    <first_received>June 23, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>September 15, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR) HCV RNA PCR &lt;25 IU/mL 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Serious adverse events, adverse events grade 3 and above</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02485080</url>
  </study>
  <study rank="72">
    <nct_id>NCT00752544</nct_id>
    <title>TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435350</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015418</other_id>
    </other_ids>
    <first_received>September 11, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>April 26, 2010</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine the short-term safety and tolerability of TMC435350 in healthy Japanese male volunteers after single and multiple doses and determine the plasma pharmacokinetics of TMC435350 after single and multiple doses.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00752544</url>
  </study>
  <study rank="73">
    <nct_id>NCT00938899</nct_id>
    <title>TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435350; Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs/>
    <other_ids>
      <other_id>CR012610</other_id>
    </other_ids>
    <first_received>July 10, 2009</first_received>
    <start_date>January 2007</start_date>
    <completion_date>September 2007</completion_date>
    <last_updated>May 18, 2011</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine the safety, tolerability and pharmacokinetics of TMC435350 after single oral doses from 50 mg up to 1200 mg and after 5 days of dosing from 50 mg up to 400 mg or up to Multiple dosing.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00938899</url>
  </study>
  <study rank="74">
    <nct_id>NCT01349465</nct_id>
    <title>3-year Follow-up Study in Patients Previously Treated With a TMC435 for the Treatment of Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">No treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>249</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs/>
    <other_ids>
      <other_id>CR017365</other_id>
      <other_id>TMC435HPC3002</other_id>
      <other_id>2010-019843-20</other_id>
    </other_ids>
    <first_received>April 26, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>November 20, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients who achieved sustained virologic response (SVR) at the last visit of previous study</outcome_measure>
      <outcome_measure>Change in sequence of HCV NS3/4A region over time in patients with confirmed detectable HCV RNA at the last visit of the previous study</outcome_measure>
      <outcome_measure>Change in sequence of the HCV NS3/4A region in patients with late relapse</outcome_measure>
      <outcome_measure>Assessment of development of liver disease progression in patients previously treated with a TMC435-containing regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Poland</country>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01349465</url>
  </study>
  <study rank="75">
    <nct_id>NCT02103699</nct_id>
    <title>A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">No intervention</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Scientific Affairs, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>317</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR101973</other_id>
      <other_id>TMC435HPC4003</other_id>
    </other_ids>
    <first_received>February 18, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>October 2, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Patients who Achieve Sustained Virologic Response(SVR)</outcome_measure>
      <outcome_measure>Determination of Prognostic Factors of Virologic Response</outcome_measure>
      <outcome_measure>Total duration of therapy</outcome_measure>
      <outcome_measure>Number of Patients who Discontinue Therapy by reason</outcome_measure>
      <outcome_measure>Number of Patients who Achieve Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Number of Patients who Achieve Sustained Virologic Response(SVR) Among Participants who Achieve Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Number of Patients who Achieve Sustained Virologic Response(SVR) According to Patient Demographics, Baseline Disease Characteristics, Treatment Paradigm, and Select Practice Setting Features</outcome_measure>
      <outcome_measure>Number of Patients With On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Number of Patients With Viral Relapse</outcome_measure>
      <outcome_measure>Number of Patients With Adverse Events by Grade and Causality</outcome_measure>
      <outcome_measure>Number of Patients With Changes in Clinical Laboratory Parameters by Grade and Causality</outcome_measure>
      <outcome_measure>Number of Patients With Adverse Event Determined to be Related to Simeprevir</outcome_measure>
      <outcome_measure>Number of Patients With Serious Adverse Event</outcome_measure>
      <outcome_measure>Number of Patients who Develop Mutations at the Time of Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Florida</state>
      <state>Kentucky</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02103699</url>
  </study>
  <study rank="76">
    <nct_id>NCT01202825</nct_id>
    <title>TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC647055</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017035</other_id>
      <other_id>TMC647055HPC1001</other_id>
    </other_ids>
    <first_received>September 14, 2010</first_received>
    <start_date>April 2010</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>March 1, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The number of participants with adverse events per type as a measure of safety and tolerability after increasing single and multiple oral doses in healthy volunteers.</outcome_measure>
      <outcome_measure>Plasma and urine concentration of TMC647055 after increasing single and multiple oral doses in healthy volunteers in fed conditions.</outcome_measure>
      <outcome_measure>Plasma concentration of TMC647055 after a single oral dose in healthy volunteers in fasted conditions as compaired to fed conditions.</outcome_measure>
      <outcome_measure>Plasma concentration of TMC647055 after 6 days oral dosing in chronic HCV-genotype 1 infected patients.</outcome_measure>
      <outcome_measure>The number of participants with adverse events per type as a measure of safety and tolerability after 6 days oral dosing in chronic HCV-genotype 1 infected patients.</outcome_measure>
      <outcome_measure>Plasma concentration of TMC647055 after a single oral dose in healthy volunteers in fasted conditions as compared to fed conditions.</outcome_measure>
      <outcome_measure>The number of participants with adverse events per type as a measure of safety and tolerability after 6 days of TMC647055, after 10 days co-administration of TMC647055 and TMC435 and after 6 days of TMC435 in chronic HCV-genotype 1 infected patients.</outcome_measure>
      <outcome_measure>Plasma concentration of TMC647055 and TMC435, if applicable, in chronic HCV-genotype 1 infected patients.</outcome_measure>
      <outcome_measure>HCV RNA decrease will be measured at the tested dose(s) and regimen(s) in chronic HCV-genotype 1 infected patients.</outcome_measure>
      <outcome_measure>HCV RNA will be measured in chronic HCV-genotype 1 infected patients.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01202825</url>
  </study>
  <study rank="77">
    <nct_id>NCT02455167</nct_id>
    <title>Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprivir (SMV)</intervention>
      <intervention type="Drug">Sofosbuvir (SOF)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-0919</other_id>
      <other_id>UL1TR001082</other_id>
    </other_ids>
    <first_received>April 21, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 2, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation</outcome_measure>
      <outcome_measure>Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02455167</url>
  </study>
  <study rank="78">
    <nct_id>NCT02214420</nct_id>
    <title>SMV + SOF With/Without RBV for IFN-II Patients With CHC</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SC Liver Research Consortium, LLC</lead_sponsor>
      <collaborator>Janssen, LP</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PJPIIS-01-14</other_id>
    </other_ids>
    <first_received>August 8, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>November 27, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>New York</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02214420</url>
  </study>
  <study rank="79">
    <nct_id>NCT02485262</nct_id>
    <title>Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Arrowhead Regional Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1234</other_id>
      <other_id>14-25</other_id>
    </other_ids>
    <first_received>June 19, 2015</first_received>
    <start_date>November 2013</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>June 29, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR 12</outcome_measure>
      <outcome_measure>Safety and Tolerability as measured by the number of participants with AEs, Change in baseline laboratory results</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02485262</url>
  </study>
  <study rank="80">
    <nct_id>NCT02583685</nct_id>
    <title>Switching Regimen in Treating Cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 12 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 12 wk</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_SWITCH-1</other_id>
    </other_ids>
    <first_received>October 12, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SWITCH-1</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks (SVR12) after discontinuation of therapy</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>Change in health related quality of life evaluated with questionnaires</outcome_measure>
      <outcome_measure>Change in mental health evaluated with questionnaires</outcome_measure>
      <outcome_measure>Liver disease progression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02583685</url>
  </study>
  <study rank="81">
    <nct_id>NCT02470858</nct_id>
    <title>Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF+ASV</intervention>
      <intervention type="Drug">SOF+DCV+SMV</intervention>
      <intervention type="Drug">SOF+DCV+ASV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Emory University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_Triple Therapy_1</other_id>
    </other_ids>
    <first_received>June 5, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>August 6, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment.</outcome_measure>
      <outcome_measure>HCV RNA levels and change during and after treatment.</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic breakthrough and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02470858</url>
  </study>
  <study rank="82">
    <nct_id>NCT02057003</nct_id>
    <title>Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAA against HCV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
      <collaborator>Hospital Universitario Reina Sofia</collaborator>
      <collaborator>Hospital Universitario Virgen de la Victoria</collaborator>
      <collaborator>Hospital Universitario de la Princesa</collaborator>
      <collaborator>Hospitales Universitarios Virgen del RocÃ­o</collaborator>
      <collaborator>Hospital Universitario Carlos Haya</collaborator>
      <collaborator>Hospital TorrecÃ¡rdenas</collaborator>
      <collaborator>Complejo Hospitalario Universitario de Huelva</collaborator>
      <collaborator>Hospital Puerta del Mar</collaborator>
      <collaborator>Hospital Universitario Virgen Macarena</collaborator>
      <collaborator>Hospital de La LÃ­nea</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPAVIR-DAA</other_id>
    </other_ids>
    <first_received>January 6, 2014</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients who achieve SVR to DAA-based therapy as measure of efficacy</outcome_measure>
      <outcome_measure>Number of patients who develop severe adverse events as measure of safety</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to a BOC-based regimen as compared to numbers of patients who achieve SVR to a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who reach undetectable HCV-RNA at week 4 of PI-based therapy as a measure of on-treatment response to therapy.</outcome_measure>
      <outcome_measure>Number of patients who develop adverse events during a BOC-based regimen as compared to numbers of patients who develop adverse events during a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to an interferon-free regimen.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02057003</url>
  </study>
  <study rank="83">
    <nct_id>NCT02333292</nct_id>
    <title>Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">SMV</intervention>
      <intervention type="Drug">DCV</intervention>
      <intervention type="Drug">LED</intervention>
      <intervention type="Drug">PTV/OTV</intervention>
      <intervention type="Drug">DBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GEHEP-MONO</other_id>
    </other_ids>
    <first_received>December 15, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>FPSMON201401</acronym>
    <primary_completion_date>November 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Patients with Sustained Virological Response</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events</outcome_measure>
      <outcome_measure>Identification of predictors of SVR</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients that receive methadone maintenance therapy</outcome_measure>
      <outcome_measure>Analyze efficacy and safety according to previous treatment outcome</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients with cirrhosis</outcome_measure>
      <outcome_measure>Evaluate impact of SVR on biological, elastographical and clinical parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02333292</url>
  </study>
  <study rank="84">
    <nct_id>NCT02531269</nct_id>
    <title>Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Basel Institute of Clinical Epidemiology (BICE)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-319</other_id>
    </other_ids>
    <first_received>August 11, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR4</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>On-treatment Virological response at week 4 assessed by measuring viral load</outcome_measure>
      <outcome_measure>Virological response at the end of treatment (EOT) assessed by measuring viral load</outcome_measure>
      <outcome_measure>The occurrence of virological failure (on-treatment and relapse) assessed by measuring viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02531269</url>
  </study>
  <study rank="85">
    <nct_id>NCT02393365</nct_id>
    <title>Prevalence and Screening of Hepatitis C in Belgium in 2015</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaire</intervention>
      <intervention type="Procedure">HCV serology</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brugmann University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHUB-HCV screening</other_id>
    </other_ids>
    <first_received>March 9, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>July 16, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV risk factors questionnaire</outcome_measure>
      <outcome_measure>Positive/Negative Hepatitis C serology</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02393365</url>
  </study>
  <study rank="86">
    <nct_id>NCT02597270</nct_id>
    <title>An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Janssen-Cilag Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR107065</other_id>
      <other_id>TMC435HPC4012</other_id>
    </other_ids>
    <first_received>November 3, 2015</first_received>
    <start_date>January 2016</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>November 27, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MAPPING</acronym>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With HCV NS3/4a Protease and NS5A Protein</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02597270</url>
  </study>
</search_results>
